The Zika (ZIKV) epidemic has spread into the three French Overseas Departments in the Caribbean (DFAs). It is therefore urgent to set up tools to collect clinical and paraclinical data for the evaluation of potential complications due to having ZIKV infection during pregnancy. This study is meant to collect, within usual care practices, clinical and paraclinical information which will allow the precise description of the consequences of ZIKV infection occurring during pregnancy.

This is a prospective observational, non-interventional study that has been integrated into the usual standard of care practices. All information and biological samples collected during the course of this project will be done through the new medical standard of care which has been put in place during the ZIKV epidemic in the DFAs; this new standard of care is a result of existing recommendations from medical professionals and/or public health authorities. Outside of these recommendations, no invasive procedure will be done simply to satisfy an objective of this study.

M1:

Inclusion Criteria:

• On-going pregnancy regardless the presumed date of birth
• Clinical signs suggestive of ZIKV infection
• Whatever the RT-PCR analysis

Exclusion Criteria:

• Minor
• No consent

M2:

Inclusion Criteria:

• Head circumference < 5th percentile
• Other brain morphological abnormality
• Hydramnios
• Intrauterine growth restriction (IUGR)

Exclusion Criteria:

• Minor
• No consent

M3:

Inclusion Criteria:

• Pregnant woman during epidemic period of ZIKV

Exclusion Criteria:

• Minor
• Opposition

M4:

Inclusion Criteria:

• Delivery during epidemic period of ZIKV

Exclusion Criteria:

• Minor
• No consent

M5:

Inclusion Criteria:

• Spontaneous abortion or fetal death in utero during epidemic period of ZIKV

Exclusion Criteria:

• Minor
• No consent

The population of this study is women who have been pregnant during the 2016 ZIKV Epidemic in the DFAs. Five study arms (hereafter called 'modules') have been defined with various inclusion criteria for each module.

M1: Pregnant women with clinical signs of acute ZIKV infection

Module 2: Pregnant women for which an abnormality has been detected in the fetus.

Module 3: Bio-bank of serum, collected once per trimester, from all pregnant women.

Module 4: Bio-bank of maternal blood and infant cord blood, taken the day of birth in all mothers and their babies in the 3 DFAs.

Module 5: Bio-bank of maternal blood and fetal tissues from women in whom the pregnancy was terminated due to miscarriage, abortion on medical grounds, or a fetal death in-utero.